Close Menu

Enzymatics

The appeals court agreed with a previous ruling that found New England Biolabs failed to file its lawsuit in a timely manner.

The firm landed Enzymatics' enzyme solutions unit in the December 2014 acquisition. It also plans to repurchase outstanding convertible notes.

Qiagen said that Enzymatics' portfolio of reagents are estimated to be used in more than 80 percent of all global NGS sequencing reactions.

BioInnovation Solutions, formerly Pathogenica, and Enzymatics are developing a rapid Ebola diagnostic and have validated it on patient samples in Nigeria.

Enzymatics has launched version 3.0 of its Archer Analysis Pipeline. It's the latest incarnation of the company's next-generation sequence analysis platform for detecting and characterizing cancer-causing gene fusions and mutations from clinical samples.

Enzymatics this week launched a targeted sequencing assay today for detecting and identifying fusions of 26 genes associated with sarcoma.

Cancer diagnostic labs have started to test next-gen sequencing-based assays from two companies, Fusion Genomics and Enzymatics, to detect gene fusions as a complement and possible alternative to existing assays.

Reagent provider Enzymatics has commercialized a new targeted sequencing technology that allows customers to detect cancer-relevant gene fusions from RNA, and has plans to offer additional catalog and custom assays to study fusion transcripts as well as DNA variants.

NEW YORK (GenomeWeb News) – Following a Massachusetts court's decision not to rule on the merits of a case involving the alleged theft of intellectual property, New England Biolabs said on Wednesday that it plans to appeal the decision.

NEW YORK (GenomeWeb News) – Enzymatics today announced it has bought ArcherDx, a developer of kits and software solutions for next-generation sequencing, for up to $50 million.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.